QurAlis to Present Data That Show its Splice-Switching ASOs Restore UNC13A Function in ALS and Frontotemporal Dementia
SV investment has resulted in the approval of 24 novel therapeutics
SV Health Investors bolsters senior biotech team - appoints Nikola Trbovic as Managing Partner and hires Jamil Beg as Partner
Hightop Health adds industry veteran to Board of Directors - Seasoned CEO and McLean Hospital Board Chair joins Hightop’s executive leadership
Merck to Acquire Caraway Therapeutics, Inc.
EyeBio Announces Expansion of Series A to $130 Million, Advances Development of Restoret for Retinal Diseases
SV Health Investors partners with HIT Executives Dave Dyell and Marc Hirshfield to Lead Recapitalization of Innovative Consulting Group
- 20 April 2021Portfolio NewsMestag Therapeutics launches with seed financing of $11 million to develop therapeutics targeting activated fibroblast populations across inflammatory disease and cancer
- 15 April 2021Portfolio NewsSutro Biopharma Earns Milestone Payment from Cytokine Derivatives Collaboration with Merck
- 15 April 2021Portfolio NewsSitryx further strengthens leadership team with the appointment of Iain Kilty, Ph.D., as Chief Scientific Officer
- 15 April 2021Portfolio NewsAlchemab raises £60M ($82M) in Series A financing to advance novel platform for identifying disease-modifying antibody therapeutics
- 12 April 2021Portfolio NewsXilio Therapeutics Strengthens Management Team with R&D Leadership Appointments
- 7 April 2021Portfolio NewsArtios Pharma Announces Collaboration with Novartis to Create Next Generation DDR Cancer Therapies
- 3 April 2021SV NewsUK vaccine supremo Kate Bingham: ‘The bickering needs to stop’
- 30 March 2021Portfolio NewsPionyr Immunotherapeutics Collaborates with Lonza to Support their Oncology Product Development
- 16 March 2021Portfolio NewsAlchemab and Medicines Discovery Catapult to develop landmark novel antibody therapy for Huntington’s disease
- 24 February 2021Portfolio NewsXilio Therapeutics Raises $95 Million in Series C Financing to Advance Potent Tumor-Selective Immuno-Oncology Pipeline
- 11 February 2021Portfolio NewsArtios Pharma Announces the Start of First Clinical Study with the Dosing of its ATR Inhibitor, ART0380, to Patients
- 26 January 2021Portfolio NewsBicycle Therapeutics Announces Publication of Article Highlighting Preclinical Data of Tumor-Targeted Immune Cell Agonists (TICAs™) in the Journal for ImmunoTherapy of Cancer